Nasal Glucagon (NG) + Glucagon IM
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Drug-specific Antibodies
Conditions
Drug-specific Antibodies, Diabetes Mellitus
Trial Timeline
Sep 1, 2013 → Dec 1, 2013
NCT ID
NCT01959334About Nasal Glucagon (NG) + Glucagon IM
Nasal Glucagon (NG) + Glucagon IM is a phase 3 stage product being developed by Eli Lilly for Drug-specific Antibodies. The current trial status is completed. This product is registered under clinical trial identifier NCT01959334. Target conditions include Drug-specific Antibodies, Diabetes Mellitus.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01959334 | Phase 3 | Completed |